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Background/aim: To prospectively assess the effects of panretinal photocoagulation (PRP) treatment on pulsatile ocular blood flow
(POBF) in patients with proliferative diabetic retinopathy (PDRP).
Materials and methods: The study included 40 eyes with PDRP in 27 patients. The PRP treatments were completed in 3 sessions with
3-week intervals. The intraocular pressure (IOP), pulse amplitude (PA), pulse volume (PV), and POBF changes that arose during the
sessions were recorded using a blood flow analyzer.
Results: The average age of the patients was 57.37 ± 11.14 years. The pre-PRP basal IOP, PA, PV, and POBF values were 20.44 ± 4.13
mmHg, 4.23 ± 1.73 mmHg, 6.89 ± 2.28 µL, and 21.86 ± 5.83 µL/s, respectively. One month after the completion of the PRP sessions,
the values were 18.49 ± 4.44 mmHg, 2.78 ± 1.13 mmHg, 5.27 ± 2.08 µL, and 15.89 ± 5.05 µL/s, respectively, and the differences were
significant (P = 0.001, P < 0.0001, P < 0.0001, and P < 0.0001, respectively).
Conclusion: PRP treatment reduces the choroidal blood flow and consequently causes significant decreases in IOP, PA, PV, and POBF.
Key words: Diabetic retinopathy, choroidal blood flow, intraocular pressure, laser coagulation, regional blood flow, retinal diseases

1. Introduction
Diabetes mellitus (DM), an important and common
endocrine disorder, results in micro- and macrovascular
complications in many organs in direct proportion to the
duration and degree of hyperglycemia (1–3). Diabetic
retinopathy (DRP), an important complication caused by
the disease, is the main cause of acquired blindness (4,5).
Panretinal laser photocoagulation (PRP) is still valid for the
prevention of complications in DRP treatment (6).
Using the devices developed in recent years, many
researchers have carried out studies related to ocular blood
flow (7–11). Ocular blood flow is pulsatile and is affected
by intraocular pressure (IOP) changes (12). The relationship
between IOP changes during the cardiac cycle and ocular
volume was reported for the first time in 1962 (13). In the
ensuing years, an instrument was developed to measure
ocular volume changes arising as a result of IOP (14). This
instrument is a modified pneumotonometer for recording
eye pulses. The rhythmic changes in IOP during the cardiac
cycle are called pulse waves, and such waves are sent by the
pneumotonometer to the instrument and converted into
digital data therein. The currently used pulsatile ocular
blood flow (POBF) analyzer (Paradigm Medical Industries,
* Correspondence: doktorademturk@yahoo.com
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Inc., Salt Lake City, UT, USA) works with a similar principle
(15).
It was reported that the impairment of ocular blood flow
is a risk factor for the development of some ocular diseases
such as glaucoma, age-related macular degeneration
(ARMD), and cataracts (16–19). Therefore, measuring
ocular blood flow and knowing the causes of ocular blood
flow disturbances are very important issues. To date, many
studies have been conducted on ocular blood flow in DM
patients (7,20,21). In such a study, Savage et al. (7) reported
lower POBF values in patients subjected to PRP treatment
compared to patients who did not undergo PRP treatment.
Their study included a comparison between PRP cases and
non-PRP cases (7). However, POBF values can be affected by
individual demographic factors such as age, sex, IOP, corneal
thickness, refraction error, and systemic hypertension (22–
27). Hence, this study was designed to evaluate the possible
impact of PRP on POBF. Patients with high-risk proliferative
DRP were prospectively evaluated for POBF before and after
PRP sessions. Thus, the study design may provide advantages
for better elucidating the effects of PRP on POBF within the
same individual rather than a comparison of measurements
obtained from different individuals.
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2. Materials and methods
This prospective study consisted of consecutive proliferative
diabetic retinopathy (PDRP) patients and was carried out
at the Department of Ophthalmology, School of Medicine,
Karadeniz Technical University, Trabzon, Turkey. Consent
of the medical ethics committee was obtained for the study
protocol.
2.1. Inclusion and exclusion criteria for the study
The study included patients over 18 years old with DM
(type I or type II) who were treated with oral hypoglycemics
and/or insulin and were diagnosed with high-risk PDRP
in the ophthalmic examination. Informed consent was
provided by each patient included in the study. The
exclusion criteria were as follows: patients with findings
of uveitis, glaucoma, retinal vascular occlusion, vitreous
hemorrhage, or exudative ARMD; patients treated with
intravitreal injection or retinal laser photocoagulation;
any prior intraocular surgery; media opacity inhibiting
a retinal examination; patients with only 1 eye; any
corneal pathology; or any other ocular problem, such as
nystagmus, preventing POBF measurement.
A detailed medical history including the age of onset
and duration of diabetes, existence of hypertension or
any other systemic disease, and medications used was
taken during the initial patient examination. All patients
underwent a biomicroscopic ophthalmologic examination
that included the anterior and posterior segments, and
the pupils were dilated in both eyes. Normal and redfree fundus images (Canon 60UVi, Japan) were taken.
The criteria for the Early Treatment Diabetic Retinopathy
Study (ETDRS) (28) were taken into consideration for the
diagnosis of diabetic retinopathy on the fundus images,
and all ophthalmologic examinations were performed by
the same researcher. The cases approved for PRP treatment
as a result of the examinations were included in the study.
The demographic and clinical findings of each case were
recorded.
2.2. Ocular blood flow measurements
Ocular blood flow measurements were performed 4 times
in total during the study. The first measurement was taken
prior to the first PRP treatment (baseline, first visit), the
second prior to the second PRP treatment (second visit),
the third prior to the third PRP treatment (third visit), and
the fourth 1 month after the completion of PRP (fourth
visit). Systemic blood pressure was also recorded at each
of the time points.
Because ocular blood flow is affected by body posture,
the measurements were taken in a sitting position. Under
local anesthesia, 1 drop of 0.5% proparacaine (Alcaine,
Alcon Laboratories Inc., Fort Worth, TX, USA) was placed
in the conjunctival sac of the eye to be measured, and
POBF was measured after 5 min had elapsed. The same

measurement device was used for all eyes (Paradigm
DICON Blood Flow Analyzer, Paradigm Medical
Industries Inc.). All measurements were performed by the
same researcher using disposable probes in contact with
the central cornea. Five consecutive ocular blood flow
measurements of approximately 20 s each were recorded
by the instrument, and detailed instrument printouts
were taken. The mean intraocular pressure (IOP; mmHg),
pulse amplitude (PA; mmHg), pulse volume (PV; µL) and
pulsatile ocular blood flow (POBF; µL/s) values of each
measurement were recorded.
2.3. Application of panretinal photocoagulation
The PRP application was completed in 3 sessions with
3-week intervals. The laser treatment was performed with
a 532-nm wavelength argon laser device (Viridis, Quantel
Medical, Clermont-Ferrand, France). During the laser
treatment, 1500–2000 burns were applied in 3 sessions,
so as not to exceed the temporal retinal vessel arcades
surrounding the macula. The fovea was approached for a
maximum of 2 disk diameters in the temporal region and
the optic disk for a maximum of a half-disk diameter in
the nasal region. The posterior pole retina surrounding
the macula was laser etched in the first session, the
midperipheral and inferior retina in the second session,
and the remaining part of the retina in the third session.
The spot diameter, duration, and power were adjusted to
200–500 µm, 0.10–0.15 s, and 250–500 mW, respectively,
during the PRP applications. The laser was used to create
an effective retinal burn. Care was taken not to burn the
macular area within the major vessel arcades or the major
vessels and papilla during the laser sessions.
The aforementioned measurements were repeated in
all cases before each laser session and 1 month after the
completion of the laser treatments.
2.4. Statistical analysis
The results were expressed as the mean ± standard
deviation. Statistical analyses were performed using SPSS
13.0.1 (SPSS Inc., Chicago, IL, USA; License no: 9069728,
KTÜ, Trabzon, Turkey). The data were evaluated for
normality with the single-sample Kolmogorov–Smirnov
test. A repeated measures of variance analysis (with
least significant difference) was used to compare the
subsequently measured systemic blood pressures with the
IOP, PA, PV, and POBF values calculated using the POBF
analyzer device. In the statistical analysis, P < 0.05 was
considered significant.
3. Results
The study included 27 patients with DM, 15 females
(55.6%) and 12 males (44.4%), with an average age of
57.37 ± 11.14 (26–75) years. The average DM duration of
the patients was 14.33 ± 5.07 (2–25) years, and 23 (85.2%)
patients were also diagnosed with hypertension. The
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systolic and diastolic blood pressure values of all patients
measured during the 4 visits are shown in the Table. The
systolic and diastolic blood pressures did not significantly
differ between visits.
The study included a total of 40 eyes from 27 patients
with DM; 22 (55%) were right eyes and 18 (45%) were left
eyes. The IOP values of the eyes measured with the POBF
analyzer device prior to the laser treatment (first visit) and
during the subsequent visits are provided in the Table.
The IOP values significantly differed between the first visit
and any other visit (P < 0.05 for each), but they did not
significantly differ between the other visits (P > 0.05 for
each).
The PA, PV, and POBF values of the 40 eyes included
in the study as measured prior to the laser treatment (first
visit) and at the subsequent visits are provided in the Table
and Figures 1–3. The PA values between the first visit and
any other visit (P < 0.0001 for each) and between the second
visit and the fourth visit (P = 0.022) were significantly
different. However, PA did not significantly differ between
the second visit and the third visit or the third visit and the
fourth visit (P = 0.22 and 0.095, respectively).
The PV values were significantly different between
the first visit and any other visit (P < 0.05 for each) and
between the second visit and the fourth visit (P = 0.026).
However, the PV was not significantly different between
the second visit and the third visit or the third visit and the
fourth visit (P = 0.151 and 0.137, respectively).
The POBF values also significantly differed between
the first visit and any other visit (P < 0.05 for each) and
between the second visit and the fourth visit (P = 0.016).
However, they were not significantly different between the
second visit and the third visit (P = 0.478) or the third visit
and the fourth visit (P = 0.084).
One month after the completion of PRP (fourth visit),
signs of PDRP were improved to a large extent in 33 out of

40 patients (82.5%), while a rather limited improvement in
the remaining patients was also present.
4. Discussion
By investigating pulsatile ocular blood flow changes
after panretinal photocoagulation treatment in patients
with PDRP, it was found that PRP treatment reduces the
choroidal blood flow and consequently causes significant
decreases in IOP, PA, PV, and POBF.
In a study examining the values of
 ocular blood flow in
healthy adult subjects, POBF values were reported as 1512
± 347 mL/min in females and 1193 ± 312 mL/min in males
(29). In the same study, PA values were reported as 3.8 ±
1.3 mmHg in females and 3 ± 1.1 mmHg in males, and PV
values were reported as 9.4 ± 2.7 mL in females and 7.1 ±
2.9 mL in males (29).
Previous studies have reported varied results with
respect to the POBF values in DM patients. A study by
Geyer et al. (30) showed decreases in the PA and POBF
values in the early phases of DRP when compared to normal
cases and increases in the POBF values in the subsequent
phases of retinopathy without any significant difference
in PA. Langham et al. (20) stated that the POBF values in
DM patients without DRP were 12% lower compared to
the nondiabetic control group. A study by Savage et al. (7)
found no significant change in POBF in cases with earlyphase DRP compared to the normal population, but the
POBF values were significantly increased in cases with
mid- or late-phase nonproliferative DRP. The same study
reported lower POBF values in patients with PDRP who
were treated with laser photocoagulation compared to
other cases. Although our study did not involve a control
group, we also found reduced POBF values following PRP
procedure in patients with DRP.
In a study performed by MacKinnon et al. (31), the
average POBF values were 818 µL/min, 1015 µL/min,

Table. Comparison of data obtained from 4 examinations of patients with proliferative diabetic retinopathy who were treated with
panretinal photocoagulation.
Measurements
Systolic arterial pressure (mmHg)
Diastolic arterial pressure (mmHg)
Intraocular pressure (mmHg)
Pulse amplitude (mmHg)
Pulse volume (µL)
Pulsatile ocular blood flow (µL/s)
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First visit

Second visit

Third visit

150.74 ± 25.56
(100–200)
87.04 ± 11.03
(70–120)
20.44 ± 4.13
(9–30)
4.23 ± 1.73
(1.6–9.6)
6.89 ± 2.28
(3.4–13)
21.86 ± 5.83
(9.7–36.4)

147.41 ± 31.08
(100–200)
84.63 ± 12.93
(60–120)
18.02 ± 4.75
(7.9–30.2)
3.19 ± 1.6
(0.9–7.5)
6.09 ± 2.66
(2.2–11.4)
18.1 ± 6.67
(8.2–36.3)

150 ± 21.84
(120–200)
87.78 ± 10.86
(70–110)
17.97 ± 4.48
(10.3–30.1)
2.97 ± 1.32
(0.8–6.1)
5.62 ± 2.23
(1.7–9.9)
17.42 ± 6.29
(8.3–36)

Fourth visit
155.56 ± 21.9
(110–190)
86.48 ± 8.06
(80–110)
18.49 ± 4.44
(9–27)
2.78 ± 1.13
(1.1–5.3)
5.27 ± 2.08
(2.5–9.2)
15.89 ± 5.05
(8.3–28.1)

P-value
0.243
0.321
<0.0001
<0.0001
<0.0001
<0.0001
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Figure 1. A comparison of the baseline pulse amplitude (PA)
values with the average PA values in eyes with proliferative
diabetic retinopathy following treatment with panretinal
photocoagulation.

Figure 3. A comparison of the baseline pulsatile ocular blood
flow (POBF) values with the average POBF values in eyes with
proliferative diabetic retinopathy following treatment with
panretinal photocoagulation.

1097 µL/min, and 644 µL/min in diabetic patients without
retinopathy, patients with baseline DRP, in preproliferative/
proliferative patients, and in the healthy control group,
respectively. Perrott et al. (10) found POBF values of 893
µL/min in diabetic patients without retinopathy and 953
µL/min in patients with nonproliferative DRP. Although
the number of patients in the current study is not sufficient
to document normal ranges of POBF in patients with
proliferative DRP, the average pre-PRP POBF value was
1311.6 µL/min (21.86 µL/s). These POBF values were
higher than those reported, and this may be due to the
fact that all the involved patients had high-risk PDRP. The
reduction of POBF values to 953.4 µL/min (15.89 µL/s) in
parallel to the regression of PDRP findings following PRP
intervention provides further evidence for this assumption.

In a study by Takahashi et al. (9), the choroidal blood
flow in the fovea of the PRP-treated DM patients was
examined using a laser Doppler flowmeter. They found
that PRP increased the choroidal blood flow in the fovea.
In a study by Mendivil and Cuartero (32) carried out using
color Doppler ultrasonography, retinal blood flow was
reduced following PRP in 25 eyes with PDRP. Hessemer
and Schmidt (33) measured the ocular pulse amplitude in
10 eyes with PDRP using an oculo-oscillo-dynamometer
and reported a significant decrease after PRP. Savage et al.
(7) found that the POBF values measured in 54 eyes in 28
patients with PDRP after PRP were 22% lower than in the
control group. Post-PRP, Grunwald et al. (34) observed
statistically significant decreases in retinal blood flow in
eyes with PDRP. In parallel with the latest studies we found
significantly decreased POBF, PA, and PV values after PRP
treatment. This is despite the fact that we used a different
device in measurement of ocular blood flow compared to
those reports.
The exact mechanism of ocular blood flow changes
in diabetic patients is not yet known. In a POBF
analysis, Savage et al. (7) noted that the POBF does not
significantly differ between patients with early-phase
DRP and healthy controls. They related this observation
to the thought that the general choroidal circulation is
not affected by vasoconstrictors, such as protein kinase C
and endothelin I released by retinal cells, produced as a
result of DRP-induced ischemia. The same study suggested
that the vascular endothelial growth factors released in
the subsequent phase of DRP may affect the choroidal
circulation and cause an increase in blood flow. Even if the
biochemical mechanism is not completely clear, Savage
et al. (7) stated that the POBF values in PRP-treated
patients are lower than normal. The vascular endothelial
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Figure 2. A comparison of the baseline pulse volume (PV)
values with the average PV values in eyes with proliferative
diabetic retinopathy following treatment with panretinal
photocoagulation.
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growth factors released as a result of ischemia cause
vasodilatation, and this results in an increase in blood flow
(35,36). This suggests that the perfusion disorders caused
by diabetes induce a blood flow reduction in the early
phase and that the ischemia-induced release of vasodilator
and angiogenic agents in the subsequent phases causes an
increase in blood flow. The blood flow is again reduced
as a result of a decrease in the release of the vasodilator
and angiogenic agents by the cells necrosed by PRP in the
late phases. A reduction in ocular blood flow due to the
development of a choriocapillary closure following PRP
treatment is another possible explanation (33). We think
that all the above-mentioned mechanisms may be among
the cause(s) of the determined decreased POBF values
after PRP therapy.
Ocular blood flow can be affected by the systemic
arterial pressure. A study performed by Esgin et al. (26)
stated that systemic hypertension may increase POBF in
diabetic patients. A study by Perrott et al. (37) reported no
significant correlation between the systemic tension values
and POBF in diabetic patients. In addition to systemic
arterial pressure, various local and neurohormonal
factors are thought to affect blood flow regulation (38).
In our study, the systemic blood pressure values did not
significantly differ between the 4 sessions when POBF was

measured. Therefore, the possible effects of the systemic
blood pressure on the POBF measurements were excluded.
The IOP values measured in our study prior to PRP
were significantly increased compared to the post-PRP
values. Previous studies on the effect of PRP on IOP have
reported varied results. Blondeau et al. (39) reported
temporary IOP increases that recovered within a few hours
in PRP-treated DM patients. Schiødte et al. (40) found
significantly decreased IOP values in diabetic patients
in the first month after PRP. Similarly, in our study, a
significant decrease was found in the IOP levels 3 weeks
after the first PRP session. One possible cause of the lateperiod decreases in IOP is the reduction in the post-PRP
uveal blood flow.
Due to the limited number of cases involved, both
eyes of 13 out 27 patients were used for evaluations in
the study, and this represents a limitation of our study.
In conclusion, we demonstrated that PRP treatment
significantly and progressively decreases POBF. The ocular
blood flow reduction due to PRP observed in our study
is in agreement with the literature. During our study, the
PA, PV, and POBF values were also reduced following
PRP treatment. We also suggest that history of retinal
laser therapy should be taken into consideration when
evaluating the ocular blood flow of patients.
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